EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Spectinomycin as initial treatment for gonorrhea


British Medical Journal 289(6455): 1383-1383
Spectinomycin as initial treatment for gonorrhea
The prevalence of penicillinase producing Neisseria gonorrheae increased exponentially from < 0.5%, in 1978 to 6.5% of all isolates in 1982. In Jan. 1983, 1st line treatment for uncomplicated heterosexual anogenital gonorrhea was therefore changed from ampicillin and probenecid to spectinomycin. This subsequently cured 95% of cases seen. Although there was an initial fall in the monthly isolation rate of penicillinase producing N. gonorrhoeae after the introduction of spectinomycin, this was not maintained. The exponential increase in the prevalence of the strain did slow in 1983, rising to only 8.7%. This, however, may have reflected a general decline in the rate of increase of penicillinase producing N. gonorrheae throughout Britain. The failure to influence the prevalence of penicillinase producing N. gonorrheae to any great degree may have been due in part to spectinomycin resistance in both penicillinase producing and non-penicillinase-producing N. gonorrheae. All of the isolates appeared identical, apart from the presence of the 4.4 megadalton plasmid in penicillinase producing N. gonorrheae, but they could not be linked epidemiologically. Changing treatment in only 1 of the many venereal diseases clinics in London [UK], where patients have open access to all such clinics, is unlikely to affect the prevalence of penicillinase producing N. gonorrheae. This has probably been more important than spectinomycin resistance in limiting the effectiveness of spectinomycin in reducing the prevalence of the strain.


Accession: 006459317

PMID: 6238647

DOI: 10.1136/bmj.289.6455.1383



Related references

SpectinOmycin sulfate and aqueous procaine penicillin G in treatment of female gonorrhea fNeiaseria gonorrhea. Antimicrob Agents Chemotherap 1965: 689-692, 1966

Spectinomycin in the treatment of gonorrhea. Ceskoslovenska Dermatologie 57(4): 217-223, 1982

Treatment of gonorrhea with spectinomycin. Harefuah 91(12): 449-450, 1976

Treatment of gonorrhea using spectinomycin. Zeitschrift für Hautkrankheiten Suppl 1: 62-67, 1977

The use of pefloxacin and spectinomycin in the treatment of gonorrhea. Giornale Italiano di Chemioterapia 38(1-3): 59-60, 1991

Spectinomycin--a new antibiotic in the treatment of gonorrhea. Lijecnicki Vjesnik 94(4): 194-196, 1972

Spectinomycin vs tetracycline for the treatment of gonorrhea. New England Journal of Medicine 296(16): 889-894, 1977

Minute treatment of gonorrhea with spectinomycin. Zeitschrift für Hautkrankheiten 49(15): 667-670, 1974

The treatment of gonorrhea with spectinomycin and rifampicin. Delaware Medical Journal 42(11): 353-355, 1970

Spectinomycin in the treatment of complications of gonorrhea in men. Przeglad Dermatologiczny 71(5): 477-482, 1984